Posted by Michael Wonder on 19 Jun 2022
IP waiver for COVID vaccines is a threat to future innovation
20 June 2022 - The decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have a negative impact on future innovation.
Medicines Australia is disappointed by the decision made at the WTO Ministerial Conference in Geneva, to adopt an intellectual property waiver – known as the Trade-Related Aspects of Intellectual Property Rights (TRIPS) waiver – for COVID-19 vaccines.
